Avanafil
- Level
- Commodity
- Parent
- 51413200
- Below
- 0
- Links · KBLI
- 8
Definition
UNSPSC 51413213This classification denotes a cgmp phosphodiesterase inhibitor with the molecular structure C23H26CLN7O3, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier, DR5S136IVO chemically known as 5-pyrimidinecarboxamide, 4-(((3-chloro-4-methoxyphenyl)methyl)amino)-2-((2s)-2-(hydroxymethyl)-1-pyrrolidinyl)-n-(2-pyrimidinylmethyl)-, but more commonly known as avanafil, which bears U.S. NIH Compound Identifier 9869929. European Medicines Agency schedules Avanafil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB34916. The term AVANAFIL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, volume 19, no. 3, 2005, list 54).
Same parent
Under 51413200 · 13Activities that produce or sell this
KBLI · 8Inherited from family 51410000.
Warning
The links were generated with a large language model (Gemini 3.5 Flash), matching UNSPSC at the family level to KBLI at the kelompok level. Some of them maybe are wrong, so check any link you intend to rely on.